DSMB hits pause on Voy­ager's Neu­ro­crine-part­nered Parkin­son's gene ther­a­py

Voy­ager Ther­a­peu­tics’ clin­i­cal plans have hit an­oth­er snag.

The Cam­bridge biotech dis­closed in their third quar­ter earn­ings Mon­day that the da­ta safe­ty and mon­i­tor­ing board has rec­om­mend­ed halt­ing en­roll­ment on their piv­otal Phase II tri­al test­ing their lead gene ther­a­py for Parkin­son’s dis­ease. Voy­ager and their part­ner Neu­ro­crine had al­ready paused en­roll­ment be­cause of Covid-19, but will now post­pone plans to re­sume the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER